TIDMOXB

RNS Number : 7699S

Oxford Biomedica PLC

13 March 2023

Oxford Biomedica confirms no exposure to SVB receivership

Oxford, UK - 13 March 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a leading gene and cell therapy group, notes the statement by the US Treasury, Federal Reserve, and FDIC on 12 March 2023 announcing measures to protect all depositors of Silicon Valley Bank ("SVB") in the United States.

Oxford Biomedica Solutions LLC, the Company's U.S. based subsidiary, maintains both a checking and deposit account with SVB. The Company has no accounts with SVB in the UK. Oxford Biomedica confirms it has no balance sheet risk exposure to the SVB receivership issue.

-Ends-

Enquiries :

Oxford Biomedica plc:

Stuart Paynter, Chief Financial Officer - T: +44 (0)1865 783 000

Taylor Boyd, VP, Head of IR - T: +1 (984) 268 8488 / E: ir@oxb.com

Sophia Bolhassan, VP, Corporate Affairs and IR - T: +44 (0) 7394 562 425 / E: ir@oxb.com

Consilium Strategic Communications:

T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com

   Mary-Jane Elliott / Matthew Cole            / Matthew Neal

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector(R) platform, and is working on programmes from pre-clinical to commercial stage across a range of therapeutic areas with global partners.

Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In 2022, the Group established Oxford Biomedica Solutions, a US based subsidiary AAV manufacturing and innovation business, based near Boston, US.

Further information is available at www.oxb.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFLFVLVLIVLIV

(END) Dow Jones Newswires

March 13, 2023 07:33 ET (11:33 GMT)

Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Oxford Biomedica Charts.
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Oxford Biomedica Charts.